Key Highlights
- 48% was the fall in Fractyl Health (NASDAQ:GUTS) to USD 2.17 from an October 15 close of USD 4.16 (own arithmetic), after the October 16, 2026 release showed weight regain of 5.1% for Revita versus 8.2% for sham, a met co-primary endpoint.
- 40% was the premarket fall in MDxHealth (NASDAQ:MDXH) to USD 0.3601, after preliminary third quarter revenue of USD 22.7 million missed consensus and USD 110 million to USD 115 million of guidance was suspended. Lake Street and Craig-Hallum moved to Hold.
- 21% was the fall in Curis (NASDAQ:CRIS) to USD 0.4022, which is 73% below the USD 1.50 price of its August 13, 2026 offering (own arithmetic). Cash was USD 5.1 million at June 30, and the 10-Q cites going concern doubt.
- USD 757,000 was the cash balance of Loop Industries (NASDAQ:LOOP) on October 13, 2026, against a quarterly net loss of USD 2.99 million. Published market data showed USD 0.3248, down 12.74%, and two Nasdaq deficiency notices are open.
Fractyl Health (NASDAQ:GUTS)
Fractyl reported six-month data on October 16, 2026 from the REMAIN-1 pivotal cohort of 308 adults who first lost at least 15% of body weight on tirzepatide. Revita patients retained 80% of that loss versus 67% for sham, with a p-value of 0.0023. The gap of 3.1 percentage points is modest (own arithmetic), the 3.8% subgroup result is post hoc, and the 12-month co-primary endpoint reads out in the first quarter of 2027. Relative volume was 43.45, and turnover of USD 18.5 million was 33.5% of the USD 55.18 million market capitalisation (own arithmetic). Per the 10-Q, cash was USD 47.1 million at June 30, 2026 with going concern doubt, and a 1-for-12 reverse split took effect on October 2. Published market data lists a Strong buy consensus, not independently confirmed. The risk for Fractyl Health (NASDAQ:GUTS) is funding beyond mid-February 2027, since a late 2026 De Novo filing needs capital and new shares or warrants dilute holders. The lead plaintiff deadline in a class action is October 20, 2026.
MDxHealth (NASDAQ:MDXH)
Per the company release of October 15, 2026, preliminary third quarter revenue from continuing operations was USD 22.7 million, flat on the prior year and 7.5% below the USD 24.55 million consensus (own arithmetic). The chief executive attributed the miss to unexpected sales force turnover. A diagnostics company earns revenue when physicians order tests, so lost representatives cut volume: tissue-based volume fell 11% to 11,232, while liquid-based volume rose to 11,792 from 4,600. Non-current loans were USD 96.4 million at June 30 and total equity was negative USD 30.4 million, with covenant compliance listed as a risk. Cash was USD 31.7 million at September 30. A Nasdaq minimum bid notice dated July 2 carries a cure period ending December 29, 2026 (own arithmetic). Lake Street cut its target to USD 0.50 from USD 3, so the rating is Hold, not Buy. The risk for MDxHealth (NASDAQ:MDXH) is a covenant or bid price breach, with the call due November 12, 2026.
Curis (NASDAQ:CRIS)
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. The latest capital event was the August 13 offering of 3,733,334 shares at USD 1.50 with matching warrants at USD 1.75, which added USD 4.8 million net. Cash was USD 5.1 million at June 30 against USD 18.6 million used in operations over six months, or USD 3.1 million a month. Adding the offering gives a runway of 3.2 months from June 30, ending in the first week of October 2026 (own arithmetic, excluding undisclosed at-the-market sales). An at-the-market program allows up to USD 100 million of sales, capped at one-third of public float. A 1-for-20 reverse split took effect on July 6, and royalty revenue ended with the November 2025 Erivedge sale. Published market data lists a Strong buy consensus, not independently confirmed, and a market capitalisation of USD 840,630 that omits the August shares. The 10-Q cover showed 2.09 million shares on August 11; adding the offering gives 5.82 million, or USD 2.34 million at USD 0.4022 (own arithmetic). The risk for Curis (NASDAQ:CRIS) is another raise far below USD 1.50, and each share sold dilutes holders.
Loop Industries (NASDAQ:LOOP)
Loop is developing a process that depolymerizes used polyester into recycled PET resin. Per the 10-Q, the net loss was USD 6.37 million for six months ended August 31, 2026, revenue was USD 296,000 from services only, and management states that cash plus the credit facility will not fund the next twelve months. Cash of USD 757,000 plus USD 629,000 of available credit totals USD 1.39 million, which covers 1.4 months of the latest quarterly loss (own arithmetic). Funding comes from an at-the-market program that sold 428,203 shares for USD 466,000 gross, borrowings of USD 1.41 million and an India joint venture. Nasdaq notices dated July 24 and July 27 set cure deadlines of January 20 and January 25, 2027. Published market data lists a Strong buy rating, not independently confirmed. The risk for Loop Industries (NASDAQ:LOOP) is a financing need within months, and no raise is announced.
Where Things Stand
Ratings did not protect these prices because each company carries a funding or event risk that a consensus label does not price. Months of cash runway, shortest first (own arithmetic, measurement dates differ): Loop 1.4 months from October 13; Curis 3.2 months from June 30; Fractyl 7.4 months from June 30; MDxHealth 12.7 months from September 30, assuming its implied USD 7.5 million quarterly cash decline persists. The largest falls hit the longer runways, so they were event-driven. Fractyl Health (NASDAQ:GUTS) adds a funding gap in mid-February 2027, and Curis has the smallest market capitalisation. Next dates: the October 20 plaintiff deadline, November 12 MDxHealth call and January 2027 Loop deadlines.






Please wait processing your request...